Abstracts

Bioequivalence of Two Pediatric Formulations Vs Adult Tablet Formulation of Cobicistat

Background: There are limited antiretroviral pharmacoenhancers available for pediatric use. Cobicistat (COBI) is a mechanism-based CYP3A inhibitor devoid of antiretroviral activity approved for adults as a pharmacoenhancer of atazanavir 300 mg or darunavir 800 mg in the European Union and as a pharmacoenhancer in the single tablet regimen elvitegravir/COBI/emtricitabine/tenofovir disoproxil fumarate (ECF/TDF; Stribild™) for treatment…

Pharmacokinetics Efficacy and Safety of an Integrase Inhibitor STR in HIV-Infected Adolescents

Background: The integrase inhibitor-based E/C/F/TDF single-tablet regimen (STR) contains elvitegravir (EVG) 150 mg, the pharmacoenhancer cobicistat (COBI) 150 mg, emtricitabine (FTC) 200 mg and tenofovir disoproxil fumarate (TDF) 300 mg. The PK, efficacy, and safety of E/C/F/TDF were evaluated in adolescents in the initial “Part A” of a prospective, 48-week, single-arm, open-label trial. Methodology: Treatment-naive…

Rilpivirine Pharmacokinetics in HIV-1-Infected Adolescents: A Substudy of PAINT (Phase II Trial)

Background: Rilpivirine (RPV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved in combination with other antiretrovirals for the treatment of HIV-1-infected, treatment-naive adults. RPV pediatric dosing has not been established. PAINT (Pediatric study in Adolescents Investigating a New NNRTI TMC278, NCT00799864) is an ongoing, open label, 48-week Phase II trial to evaluate RPV pharmacokinetics (PK),…

Safety Pharmacokinetics and Efficacy of Dolutegravir in Treatment-Experienced HIV+ Children

Background: IMPAACT P1093 is an ongoing Phase I/II multicenter open-label PK, safety, dose finding study of dolutegravir (DTG) plus optimized background regimen (OBR) in children and adolescents in age defined cohorts. Adequate pharmacokinetics (PK), safety and virologic efficacy have been described in children aged 12 to 18 years, leading to the recent FDA approval. Here…

High Nevirapine and Low Lopinavir/Efavirenz Exposures in Resource-Poor Ugandan Children

Background: Malnutrition may impact antiretroviral (ART) pharmacokinetics (PK) and clinical response in children. We evaluated the PK of nevirapine (NVP), efavirenz (EFV) and lopinavir (LPV) by nutritional status among HIV-infected children stabilized on ART in Tororo, Uganda. Methodology: Sparsely sampled dried blood ¬spot (DBS) ART samples, collected in Ugandan children residing in resource poor country…

Simulation and Exposure-Based Assessment of Pediatric Lopinavir Fixed-Dose Combination Product

Background: Currently, only one boosted PI is approved for use in infants: lopinavir/ritonavir (LPV/r). The LPV/r formulation is not ideal for infants and children living in resource-poor settings, as it is poorly tolerated, needs refrigeration, contains large amounts of undesirable excipients, and is more expensive than other regimens for most national HIV programmes. The development…

Bone and Renal Safety at 96 Weeks of TDF-Containing Regimens in HIV-Infected Thai Children

Background: Tenofovir (TDF) is currently recommended in first- and second-line ART regimens for children. This study was aimed at determining the impact of TDF on bone mineral density (BMD) and renal function among HIV-infected adolescents after 96 weeks. Methodology: Of 62 HIV-infected children on TDF-containing regimens, 35 children had CD4, HIV-RNA, BMD and renal function…

Inflammatory Biomarkers in Chronic HIV Disease Predominantly Associate With Monocyte Activation

Background: We have previously shown soluble biomarkers of inflammation, including an IL-6/D-dimer composite score, independently predict non-AIDS related morbidity and mortality. We explored associations between select biomarkers and cellular immunophenotypes to identify potential mechanisms of excess inflammation among HIV-infected adults. Methodology: Baseline plasma specimens from SUN Study participants were analyzed for levels of IL-6, hsCRP,…